Optimizing Efficacy and Tolerability of Antidepressant Therapy: Does Selectivity of Action Matter? CME
Chairperson: Michael E. Thase, MD; Faculty: Pedro L. Delgado, MD; Justine M. Kent, MD; Andrew A. Nierenberg, MD
DisclosuresRelease Date: August 21, 2003;
Valid for credit through August 21, 2004 This activity has expired.
CME in this activity indicates that it was developed according to ACCME guidelines and was certified for credit by one or more accredited CME or CE providers. Medscape cannot attest to the timeliness of expired CME activities.
This program is based on an Industry-Supported Symposium presented at the American Psychiatric Association 156th Annual Meeting. The APA was not involved in, and received no commercial support for, the development of this product and does not award CME credit for this program. This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Optimizing Efficacy and Tolerability of Antidepressant Therapy: Does Selectivity of Action Matter?" symposium held at the San Francisco Marriott in San Francisco, California on May 17, 2003.
